View Post

New ORNL AI tool revolutionizes process for matching cancer patients with clinical trials

In Clinical Trials by Barbara Jacoby

Source: DOE/Oak Ridge National Laboratory From: eurekalert.org A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials. The researchers were one of ten teams to develop a digital tool to address complex challenges relevant to medical conditions such …

View Post

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

In Clinical Trials by Barbara Jacoby

Source: NKMax America, Inc. From: prnewswire.com NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for SNK01, an autologous NK cell adoptive immunotherapy candidate for the treatment of patients …

View Post

Inovio Pharma (INO) Commences REVEAL 2 Global Phase 3 Clinical Study for the Treatment of HPV-Related Cervical Pre-cancer

In Clinical Trials by Barbara Jacoby

From: streetinsider.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the initiation and opening of sites to enroll the second portion of the company’s Phase 3 program for VGX-3100, Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The study, named REVEAL 2, is the company’s confirmatory stage Phase 3 clinical study and is designed to evaluate the …

View Post

Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

In Clinical Trials by Barbara Jacoby

Source: Celsion CORP From: globenewswire.com Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. This Phase IB study evaluated patients newly diagnosed with Stage III/IV ovarian cancer and were treated with Celsion’s DNA-based, IL-12 immunotherapy, GEN-1, in combination …

View Post

Radiation after surgery triples survival for a type of pediatric brain tumor

In Clinical Trials by Barbara Jacoby

By: St. Jude Children’s Research Hospital From: medicalxpress.com Radiation immediately following surgery in children with ependymoma, the third most common pediatric brain tumor, can nearly triple survival. The results are part of a Children’s Oncology Group (COG) clinical trial led by Thomas E. Merchant, D.O., Ph.D., of St. Jude Children’s Research Hospital. The findings appear as an advance online publication …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Digital Pills May Be on the Horizon in Cancer Care

In Clinical Trials by Barbara Jacoby

By: Andrew Smith From: onclive.com There have been many efforts in recent years to improve patient adherence to oncology medications. Sticking to a regime that causes adverse events is not easy, and sometimes simple forgetfulness is to blame, but intervention by providers has been shown to work.1 Now, oncologists may soon have 1 more tool in the form of digital …

View Post

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Bradley J. Monk, MD From: onclive.com The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that …

View Post

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab

In Clinical Trials by Barbara Jacoby

At ASCO-SITC Clinical Immuno-Oncology Symposium From: digitaljournal.com – Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy – Median overall survival not yet reached with median follow up of 14.4 months in Cohort A – Improved survival observed in patients with low CD8+ “cold” tumor at baseline …

View Post

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

In Clinical Trials by Barbara Jacoby

From: financialbuzz.com DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study …